Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

Multiple myeloma (MM) is a cancer of abnormal plasma cells, a type of white blood cell that is normally responsible for producing antibodies in the bone marrow. It is the second most common hematological malignancy in the US, and constitutes less than 1% of all cancer types. Multiple myeloma is not considered curable, but is treatable, with many therapies being generic steroids, and chemotherapies. Significant improvements in treatment outcome were achieved with the introduction of the immunomodulatory (IMiD) agents Thalomid and and Revlimid and the proteasome inhibitor (PI) Velcade. Since the early 2000s, multiple myeloma therapy has been dominated by these agents, and they can be found in every setting of the disease, and in multiple combinations. The latest drugs approved in the US, including Pomalyst, Kyprolis, Ninlaro, and Empliciti, have prolonged progression-free survival (PFS) and overall survival (OS), but patients are still becoming refractory to these drugs. Currently the only therapy class that brings clinical benefit to patients who relapse on these agents is J&J's anti-CD38 monoclonal antibody Darzalex. With the increased adoption of Darzalex in the treatment paradigm, more patients are becoming refractory to Darzalex, leading to an unmet need as currently there are no marketed therapies that can provide benefit to patients whose disease relapses following treatment with Darzalex.

The Phase III development pipeline, which includes novel therapies such as anti-BCMA biologics, selinexor, Venclexta, isatuximab, and Ygalo, will begin to address the unmet needs patients face and provide alternate treatment options to currently marketed therapies. During the forecast period from 2017–2027, GlobalData expects the multiple myeloma market to increase, due to an increase in incident cases brought about by a growing aging population across the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China (8MM), and the introduction of new premium-priced therapeutics.

Key Questions Answered

Which pipeline agents are the most promising and expected to launch in the 8MM? What are the forecasted sales of these agents and what will be their impact in the MM market?

What are the main unmet needs in MM, which pipeline drugs will fulfill these needs, and to what extent?

What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?

Key Opinion Leaders (KOLs) insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Scope

Overview of MM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized MM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027. Hybrid forecast model: incidence & prevalence.

Key topics covered include strategic competitive assessment, market characterization, unmet needs, clinical trial mapping and implications for the MM therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MM. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global MM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global MM market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MM market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

AbbVie

Amgen

Antengene

BioLineRx

Bluebird Bio

Bristol-Myers Squibb

Celgene

Genentech

Genmab

GlaxoSmithKline

F. Hoffmann-La Roche

Johnson & Johnson

Juno Therapeutics

Karyopharm Therapeutics

Legend Biotech

Novartis ...

AbbVie

Amgen

Antengene

BioLineRx

Bluebird Bio

Bristol-Myers Squibb

Celgene

Genentech

Genmab

GlaxoSmithKline

F. Hoffmann-La Roche

Johnson & Johnson

Juno Therapeutics

Karyopharm Therapeutics

Legend Biotech

Novartis

Oncopeptides

Ono

Regeneron

Sanofi

Sellas

Takeda

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Multiple Myeloma: Executive Summary

2.1 Multiple Myeloma Market Is ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Multiple Myeloma: Executive Summary

2.1 Multiple Myeloma Market Is Expected to Grow to $21.6B in 2027

2.2 Multiple Myeloma Pipeline Is Diverse, Comprising Therapies with Novel Mechanisms of Action

2.3 Opportunities Remain for More Effective and Conveniently Administered Therapies in Multiple Myeloma

2.4 Anti-BCMA Biologics Are Best Equipped to Penetrate the Multiple Myeloma Market

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 Diagnosed Incidence of MM

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Diagnosed Incident Cases of MM

5.4.4 Diagnosed Incident Cases of MM by Symptom Status

5.4.5 Diagnosed Incident Cases of MM by SCT Eligibility

5.4.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities

5.4.7 Diagnosed Incident Cases of MM by R-ISS Staging

5.4.8 Diagnosed Prevalent Cases of MM

5.5 Epidemiological Forecast for Multiple Myeloma (2017–2027)

5.5.1 Diagnosed Incident Cases of MM

5.5.2 Age-Specific Diagnosed Incident Cases of MM

5.5.3 Sex-Specific Diagnosed Incident Cases of MM

5.5.4 Diagnosed Incident Cases of MM by Symptom Status

5.5.5 Diagnosed Incident Cases of MM by SCT Eligibility

5.5.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities

5.5.7 Diagnosed Incident Cases of MM by R-ISS Staging

5.5.8 Diagnosed Prevalent Cases of MM

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.2.1 Diagnosis

6.2.2 Clinical Practice

6.3 5EU

6.3.1 France

6.3.2 Germany

6.3.3 Italy

6.3.4 Spain

6.3.5 UK

6.3.6 Japan

6.3.7 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Treatments for Patients with High-Risk Cytogenetics

8.3 Personalized Approach to Treatment Using Cytogenetic Profiles

8.4 Treatment of Heavily Pretreated Patients

8.5 Improved Route of Administration

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Takeda Portfolio Assessment

10.4 BMS and Celgene Portfolio Assessment

10.5 Amgen Portfolio Assessment

10.6 J&J Portfolio Assessment

10.7 Novartis Portfolio Assessment

10.8 Sanofi Portfolio Assessment

10.9 AbbVie and Roche Portfolio Assessment

10.10 GSK Portfolio Assessment

10.11 Karyopharm Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic/Biosimilar Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Multiple Myeloma: Key Metrics in the 8MM

Table 2: Disease Manifestation in Multiple Myeloma

Table 3: DS and ISS Systems and Their Relationships ...

Table 1: Multiple Myeloma: Key Metrics in the 8MM

Table 2: Disease Manifestation in Multiple Myeloma

Table 3: DS and ISS Systems and Their Relationships to Disease Stage

Table 4: Risk Factors for MM

Table 5: Treatment Guidelines for Multiple Myeloma

Table 6: Country Profile – US

Table 7: Country Profile – France

Table 8: Country Profile – Germany

Table 9: Country Profile – Italy

Table 10: Country Profile – Spain

Table 11: Country Profile – UK

Table 12: Country Profile – Japan

Table 13: Country Profile – China

Table 14: Leading Treatments for Multiple Myeloma, 2019

Table 15: Takeda’s Multiple Myeloma Portfolio Assessment, 2019

Table 16: BMS and Celgene’s Multiple Myeloma Portfolio Assessment, 2019

Table 17: Amgen’s Multiple Myeloma Portfolio Assessment, 2019

Table 18: J&J’s Multiple Myeloma Portfolio Assessment, 2019

Table 19: Novartis’ Multiple Myeloma Portfolio Assessment, 2019

Table 20: Sanofi’s Multiple Myeloma Portfolio Assessment, 2019

Table 21: AbbVie and Roche’s Multiple Myeloma Portfolio Assessment, 2019

Table 22: GSK’s Multiple Myeloma Portfolio Assessment, 2019

Table 23: Karyopharm’s Multiple Myeloma Portfolio Assessment, 2019

Table 24: Multiple Myeloma Market – Global Drivers and Barriers, 2017–2027

Table 25: Key Events Impacting Sales for Multiple Myeloma in the US, 2017–2027

Table 26: Multiple Myeloma Market – Drivers and Barriers in the US, 2017–2027

Table 27: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2017–2027

Table 28: Multiple Myeloma Market – Drivers and Barriers in the 5EU, 2017–2027

Table 29: Key Events Impacting Sales for Multiple Myeloma in Japan, 2017–2027

Table 30: Multiple Myeloma Market – Global Drivers and Barriers in Japan, 2017–2027

Table 31: Key Events Impacting Sales for Multiple Myeloma in China, 2017–2027

Table 32: Multiple Myeloma Market – Global Drivers and Barriers in China, 2017–2027

Table 33: Key Historical and Projected Launch Dates for MM

Table 34: Key Historical and Projected Patent Expiry Dates for MM

Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Multiple Myeloma in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in Multiple Myeloma ...

Figure 1: Global Sales Forecast by Country for Multiple Myeloma in 2017 and 2027

Figure 2: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period

Figure 3: Competitive Assessment of the Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Multiple Myeloma During the Forecast Period

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Men, Ages ≥40 Years, 2007 to 2027

Figure 5: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Women, Ages ≥40 Years, 2007 to 2027

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MM

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Symptom Status

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by SCT Eligibility

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Chromosomal Abnormalities

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by R-ISS Staging

Figure 12: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017

Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017

Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N, 2017

Figure 15: 8MM, Diagnosed Incident Cases of MM by Symptom Status, Both Sexes, Ages ≥40 Years, N, 2017

Figure 16: 8MM, Diagnosed Incident Cases of MM by SCT Eligibility, Both Sexes, Ages ≥40 Years, N, 2017

Figure 17: 8MM, Diagnosed Incident Cases of MM by Chromosomal Abnormalities, Both Sexes, Ages ≥40 Years, N, 2017

Figure 18: 8MM, Diagnosed Incident Cases of MM by R-ISS Staging, Both Sexes, Ages ≥40 Years, N, 2017

Figure 19: 8MM, Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2017

Figure 20: Patient Journey for SCT-e and SCT-i NDMM

Figure 21: Patient Journey for RRMM

Figure 22: Unmet Needs and Opportunities in Multiple Myeloma

Figure 23: Overview of the Development Pipeline in Multiple Myeloma

Figure 24: Key Phase I-II-III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for Multiple Myeloma in the 8MM During the Forecast Period

Figure 25: Competitive Assessment of the Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of Multiple Myeloma During the Forecast Period

Figure 26: Analysis of the Company Portfolio Gap in Multiple Myeloma During the Forecast Period

Figure 27: Global (8MM) Sales Forecast by Country for Multiple Myeloma, 2017 and 2027

Figure 28: Global (8MM) Sales Forecast by Therapy Class for Multiple Myeloma, 2017 and 2027

Figure 29: Sales Forecast by Class for Multiple Myeloma in the US in 2017 and 2027

Figure 30: Sales Forecast by Class for Multiple Myeloma in the 5EU in 2017 and 2027

Figure 31: Sales Forecast by Class for Multiple Myeloma in Japan in 2017 and 2027

Figure 32: Sales Forecast by Class for Multiple Myeloma in China in 2017 and 2027

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports